MRD directed consolidation in multiple myeloma-Are we there yet?

This study analyzed 761 patients with newly diagnosed multiple myeloma in a real-world Chinese setting. Findings show daratumumab-based first-line therapy significantly improves depth of remission, progression-free survival, and overall survival compared to standard induction treatments. Even with limited courses, daratumumab enhanced MRD negativity, supporting its use as a preferred initial induction therapy.